| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Risdiplam (JAN/USAN/INN); Evrysdi (TN) | ||||||
| Product | EVRYSDI (Genentech) | ||||||
| Formula | C22H23N7O | ||||||
| Exact mass | 401.1964 | ||||||
| Mol weight | 401.4643 | ||||||
| Structure |  | ||||||
| Class | Metabolizing enzyme substrate DG01891 CYP1A1 substrate DG02954 CYP2J2 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG03121 CYP3A7 substrate DG03191 FMO1 substrate DG02950 FMO3 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Protein modulator | ||||||
| Disease | Spinal muscular atrophy [DS:H00455] | ||||||
| Comment | Treatment of Spinal muscular atrophy (SMA) | ||||||
| Target | SMN2 [HSA:6607] [KO:K13129] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: FMO1 [HSA:2326], FMO3 [HSA:2328], CYP1A1 [HSA:1543], CYP2J2 [HSA:1573], CYP3A4 [HSA:1576], CYP3A7 [HSA:1551] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] M MUSCULO-SKELETAL SYSTEM M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM M09AX Other drugs for disorders of the musculo-skeletal system M09AX10 Risdiplam D11406 Risdiplam (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment Risdiplam D11406 Risdiplam (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 119 Miscellaneous 1190 Miscellaneous D11406 Risdiplam (JAN/USAN/INN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG01891 CYP1A1 substrate D11406 Risdiplam DG02954 CYP2J2 substrate D11406 Risdiplam DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D11406 Risdiplam DG03121 CYP3A7 substrate D11406 Risdiplam DG03191 FMO1 substrate D11406 Risdiplam DG02950 FMO3 substrate D11406 Risdiplam Target-based classification of drugs [BR:br08310] Not elsewhere classified Signaling molecules Spliceosome SMN2 D11406 Risdiplam (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11406 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11406 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11406 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11406 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11406 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 30 1 N4y N 11.2000 -15.1900 2 C8y C 11.2000 -16.5900 3 C8y C 12.3900 -17.2900 4 C8x C 13.6500 -16.5900 5 C8y C 13.6500 -15.1900 6 N5x N 12.3900 -14.4900 7 C8x C 9.8700 -14.7700 8 C8y C 9.0300 -15.8900 9 N5x N 9.8700 -17.0100 10 C1a C 12.3900 -18.6900 11 C1a C 7.6300 -15.8900 12 C8y C 14.8400 -14.4900 13 N5x N 16.0300 -15.1900 14 C8y C 17.2900 -14.4900 15 N4y N 17.2900 -13.0900 16 C8y C 16.1000 -12.3900 17 C8x C 14.8400 -13.0900 18 C8x C 18.4800 -15.1900 19 C8x C 19.6700 -14.4900 20 C8y C 19.6700 -13.0900 21 C8x C 18.4800 -12.3900 22 N1y N 20.8600 -12.3900 23 C1x C 22.0500 -13.0900 24 C1x C 23.3100 -12.3900 25 N1x N 23.3100 -10.9900 26 C1z C 22.1200 -10.2900 27 C1x C 20.8600 -10.9900 28 C1x C 22.8200 -9.1000 29 C1x C 21.4200 -9.1000 30 O5x O 16.1172 -10.9901 BOND 35 1 1 2 1 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 1 7 1 8 7 8 2 9 8 9 1 10 2 9 2 11 3 10 1 12 8 11 1 13 5 12 1 14 12 13 1 15 13 14 2 16 14 15 1 17 15 16 1 18 16 17 1 19 12 17 2 20 14 18 1 21 18 19 2 22 19 20 1 23 20 21 2 24 15 21 1 25 20 22 1 26 22 23 1 27 23 24 1 28 24 25 1 29 25 26 1 30 26 27 1 31 22 27 1 32 28 29 1 33 29 26 1 34 26 28 1 35 16 30 2 |